ZNTL Stock Forecast: Zentalis Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Zentalis Pharmaceuticals, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 44 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Zentalis Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (67): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (12): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ZNTL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ZNTL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Nov 2026 | Wedbush | Upgrade | Outperform | $5.00 → $6.00 |
| 19 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 5 Oct 2026 | Leerink Partners | Assumes | Outperform | $4.00 → $8.00 |
| 16 Sept 2026 | William Blair | Initiates | Outperform | — |
| 23 July 2026 | Rodman & Renshaw | Initiates | Buy | — |
| 17 July 2026 | Mizuho | Initiates | Outperform | $8.00 |
| 10 Apr 2026 | Guggenheim | Maintains | Buy | — |
| 27 Mar 2026 | Guggenheim | Reiterates | Buy | — |
| 12 Nov 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 7 Aug 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 15 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 May 2025 | Wedbush | Reiterates | Neutral | — |
| 28 Mar 2025 | Wedbush | Reiterates | Neutral | — |
| 27 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 29 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Jan 2025 | UBS | Maintains | Neutral | — |
| 15 Nov 2024 | Guggenheim | Maintains | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ZNTL.
This page is one stock. Monday covers all of them.
ZNTL appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ZNTL vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Zentalis Pharmaceuticals, Inc. returned +4.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ZNTL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 82% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −61.9%
- Return on assets
- −30.9%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Zentalis Pharmaceuticals, Inc. has a market value of $133.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$139.5M.
Free cash flow in the twelve months to 30 June 2026: −$128.1M.
Zentalis Pharmaceuticals, Inc. employs 106 people.
Data provided by Twelve Data
ZNTL and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ZNTL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Zentalis Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ZNTL
What is the ZNTL stock price forecast for 2026-2027?
The median 12-month analyst price target for Zentalis Pharmaceuticals, Inc. is $7, with estimates ranging from $5 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ZNTL stock a buy right now?
Of the 11 analysts covering Zentalis Pharmaceuticals, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zentalis Pharmaceuticals, Inc. 44 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ZNTL?
As at 21 Nov 2026, Zentalis Pharmaceuticals, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (67 of 100).
Will ZNTL stock go up?
No one can know that. What the data says: the median 12-month target from 11 analysts is $7, and Ticker Nerd's factor model ranks Zentalis Pharmaceuticals, Inc. 44 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ZNTL stock forecast for 2030?
No analyst covering Zentalis Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZNTL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $10 over the next 12 months.
How has ZNTL stock performed over the past year?
Zentalis Pharmaceuticals, Inc. returned +4.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Zentalis Pharmaceuticals, Inc. do?
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer. Its current portfolio centers on azenosertib, an oral investigational WEE1 inhibitor being advanced in studies across ovarian cancer and other solid tumors.
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer. Its current portfolio centers on azenosertib, an oral investigational WEE1 inhibitor being advanced in studies across ovarian cancer and other solid tumors. The company’s research emphasizes biomarker-driven oncology, with a focus on targeted, non-chemotherapy treatment approaches designed to address difficult-to-treat cancers. Zentalis also develops additional oncology candidates, including programs targeting hematologic malignancies and other cancer pathways, supported by its internal discovery capabilities and clinical development expertise. Headquartered in San Diego, California, Zentalis Pharmaceuticals plays a specialized role in the oncology market by advancing precision medicine candidates from discovery into late-stage clinical evaluation.
CEO Ms. Julie M. Eastland M.B.A. · 106 employees · United States · https://zentalis.com